Tech Company Financing Transactions
CytoVale Funding Round
CytoVale, based in San Francisco, secured $100 million from Sands Capital Management, Breakout Ventures and Canada Pension Plan Investment Board.
Transaction Overview
Company Name
Announced On
10/10/2024
Transaction Type
Venture Equity
Amount
$100,000,000
Round
Series D
Investors
Proceeds Purpose
Cytovale will use the funding to build upon its early clinical success and accelerate commercial expansion of IntelliSep to more hospital emergency departments (ED) and health systems nationwide.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
150 Executive Park Blvd. 4100
San Francisco, CA 94134
USA
San Francisco, CA 94134
USA
Phone
Undisclosed
Website
Email Address
Overview
We're inspired by the power of biology and driven to build tools that make it possible to access that power in new ways.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Ajay Shah
Chief Operating Officer
Jennifer Beedon
VP - Engineering
Henry Tse
Browse more venture capital transactions:
Prev: 10/10/2024: Rivermark Medical venture capital transaction
Next: 10/10/2024: Case Status venture capital transaction
Share this article
Where The Data Comes From
We do our best to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs